Small Pharma Inc. (DMTTF)
| Previous Close | 0.0900 |
| Open | 0.0940 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 0.0910 - 0.0990 |
| 52 Week Range | 0.0550 - 0.3328 |
| Volume | |
| Avg. Volume | 96,875 |
| Market Cap | 30.195M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0550 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Small Pharma Announces Update on Intellectual Property Portfolio with Two New Patents Approved for Issue
New United States patents will provide further support for the Company’s proprietary position in a key jurisdiction United States grants will bring the Company’s total to 16 granted patents and over 90 applications pending LONDON, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-duration psychedelic-assisted therapies for mental health conditions, today announces an update to its intellectua
- Baystreet
Stocks in play: Small Pharma Inc.
Announces that SPL026, intravenous N,N-Dimethyltryptamine, with supportive therapy for the treatment ...
- GlobeNewswire
Small Pharma Reports Fiscal Third Quarter 2023 Highlights
Positive top-line results from Phase IIa trial of SPL026 in Major Depressive Disorder New SPL026 trials underway and screening commenced in the first in-human study of SPL028 LONDON, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-duration psychedelic-assisted therapies for mental health conditions, has today published its financial results for the three and nine months ended November 30, 2
